Published in Br J Cancer on December 01, 1971
The growth of human tumours in immunosuppressed mice and their response to chemotherapy. Br J Cancer (1974) 1.27
Human tumour xenografts: a critical appraisal. Br J Cancer Suppl (1980) 1.08
Hormonal environment of immunosuppressed mice. Br J Cancer (1978) 0.87
Human myeloma marrow cells in immunologically deficient mice. Br J Cancer (1974) 0.75
Effect of antilymphocyte serum on the growth of Hep 2 and HeLa cells in mice. Nature (1968) 1.58
Effect of steroid hormone on activation of Endoxan (cyclophosphamide). Biochem Pharmacol (1969) 1.40
Treatment of cervical carcinoma by methotrexate (NSC-740) with cyclophosphamide (NSC-26271). Cancer Chemother Rep (1969) 1.00
A method for testing for synergy with any number of agents. J Infect Dis (1978) 9.52
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Is azathioprine a better immunosuppressive than 6-mercaptopurine? Clin Exp Immunol (1971) 3.47
Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol (1977) 2.89
Postoperative depression of the lymphocyte response to phytohaemagglutinin. Lancet (1967) 2.57
Criteria for analyzing interactions between biologically active agents. Adv Cancer Res (1981) 2.49
Deep lamellar keratoplasty on air with lyophilised tissue. Br J Ophthalmol (1992) 2.22
The expected effect of a combination of agents: the general solution. J Theor Biol (1985) 2.06
Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst (1987) 2.02
Transplantation of adenocarcinomas of the colon in mice. J Natl Cancer Inst (1975) 1.85
In vivo biological activity of the components of haematoporphyrin derivative. Br J Cancer (1982) 1.82
Chemotherapy of transplanted adenocarcinomas of the colon in mice. Cancer Chemother Rep (1976) 1.59
Transplantable colon tumors as chemotherapy screening models. Cancer (1975) 1.55
Photodynamic destruction of human bladder carcinoma. Br J Cancer (1975) 1.55
Cerebral photosensitisation by haematoporphyrin derivative. Evidence for an endothelial site of action. Br J Cancer (1986) 1.53
Impact of facial paralysis on patients with acoustic neuroma. Laryngoscope (2000) 1.51
Time-dependent immunosuppressive effects of anti-thymocyte serum. Nature (1967) 1.48
meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitisers with favourable selectivity. Br J Cancer (1986) 1.47
Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br J Cancer (1987) 1.47
Dose-response curves for agents that impair cell reproductive integrity. A fundamental difference between dose-response curves of antimetabolites and those for radiation and alkylating agents. Br J Cancer (1969) 1.44
Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer (1991) 1.42
A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst (1990) 1.38
Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Res (1974) 1.36
Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst (1989) 1.31
Depression of lymphocyte responses after surgical trauma. Br J Exp Pathol (1973) 1.29
Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs. Cancer Res (1998) 1.29
Correlations between methods for measurement of synergy. J Infect Dis (1980) 1.29
The growth of human tumours in immunosuppressed mice and their response to chemotherapy. Br J Cancer (1974) 1.27
In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents. Cancer Chemother Rep (1972) 1.26
Pharmacokinetics and anti-tumour activity of LM985 in mice bearing transplantable adenocarcinomas of the colon. Br J Cancer (1986) 1.24
Cell respiration as a requirement for antibody release in vitro. Nature (1968) 1.21
Some biological characteristics of transplantable lines of mouse adenocarcinomas of the colon. J Natl Cancer Inst (1980) 1.21
Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. Biochem J (1989) 1.19
Patient information leaflets for prostate cancer: which leaflets should healthcare professionals recommend? Patient Educ Couns (2003) 1.16
Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer (1997) 1.15
Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 3: 2-Heteroaryl derivatives. Arch Pharm (Weinheim) (1998) 1.13
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer (1993) 1.13
In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer (1992) 1.11
Synergistic effect of cortisol and prostaglandin E2 on the PHA response. Relation to immunosuppression induced by trauma. Clin Exp Immunol (1976) 1.11
Enzyme activated anti-tumour agents. Conjugates of p-hydroxyaniline mustard as substrates for hydrolytic enzymes. Biochem Pharmacol (1974) 1.07
Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status. Br J Cancer (1991) 1.03
Comparison of nitrogen-mustard sensitive and -resistant Yoshida sarcomas. Int J Cancer (1966) 1.03
The therapeutic significance of the dose response curve for antilymphocytic serum. Transplantation (1971) 1.02
The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide. Clin Exp Immunol (1973) 1.01
Immunosuppression by L-asparaginase. Nature (1970) 0.99
Quantitative angiogenesis assays in vivo--a review. Angiogenesis (2004) 0.99
Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512). Cancer Chemother Pharmacol (1989) 0.98
The relation between the physico-chemical properties and immunosuppressive effects of an homologous series of sulphonic acid esters. Immunology (1967) 0.97
Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer (1995) 0.97
Effects of L-asparaginase on lymphocyte-target cell reactions in vitro. Nature (1970) 0.95
Synergy with double and triple antibiotic combinations compared. J Antimicrob Chemother (1983) 0.95
Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative. Br J Cancer (1985) 0.94
Establishment and characterisation of new cell lines from human breast tumours initially established as tumour xenografts in NMRI nude mice. Breast Cancer Res Treat (1997) 0.94
EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer (1995) 0.93
Immunosuppressive agents: the design of selective therapeutic schedules. Antibiot Chemother (1969) 0.93
Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy. Br J Cancer (1997) 0.93
Potentiation of EO9 anti-tumour activity by hydralazine. Eur J Cancer (1993) 0.92
The rabbit VX2 tumour as a model for carcinomas of the tongue and larynx. Acta Otolaryngol (1989) 0.91
Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512). Br J Cancer (1988) 0.91
Characterisation of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies. Acta Oncol (1995) 0.91
Synergy assessment with growth curves. J Infect Dis (1984) 0.90
Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cancer Res (1989) 0.90
DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer (1992) 0.90
Radiosensitivity of immunologically activated cells. Nature (1966) 0.89
Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Br J Cancer (2003) 0.88
Minor synergy and antagonism may be clinically important. J Antimicrob Chemother (1987) 0.88
HPD - a study of its components and their properties. Adv Exp Med Biol (1983) 0.87
Flavone acetic acid--from laboratory to clinic and back. Anticancer Drugs (1993) 0.87
Selective suppression of murine antibody-dependent cell-mediated cytotoxicity by azathioprine. Transplantation (1975) 0.87
Synthesis, mechanism of action, and biological evaluation of mitosenes. J Med Chem (1989) 0.86
Experimental correlations of in vitro drug sensitivity with in vivo responses to ThioTEPA in a panel of murine colon tumours. Cancer Chemother Pharmacol (1988) 0.86
Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours. Br J Cancer (1981) 0.85
The assessment of response of murine transplantable colon tumors to combination chemotherapy. J Cancer Res Clin Oncol (1982) 0.85
Activity of N-[N'-(2-chloroethyl)-N'-nitrosocarbamoyl]-alanine and derivatives against transplantable adenocarcinomata of the mouse colon (MAC). J Cancer Res Clin Oncol (1986) 0.84
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer (2000) 0.84
Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. Pharm Res (1995) 0.84
The localization of haemolytic antibody in sections of lymphoid organs: an improved method. Immunology (1970) 0.84
Synergy and antagonism are not synonymous with therapeutic advantage and disadvantage. J Antimicrob Chemother (1988) 0.84
Cognitive dissonance, the placebo effect and the evaluation of surgical results. Clin Otolaryngol Allied Sci (2000) 0.83
Role of mitosis and mitotic inhibition in the immunosuppressive action of thioguanine. Nature (1966) 0.83
Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br J Cancer (1996) 0.83
A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer (2001) 0.83
Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines. Eur J Cancer (2001) 0.83
Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer (1999) 0.83
Drug latentiation in cancer chemotherapy. Biomedicine (1978) 0.83
Consequences of synergy between environmental carcinogens. Environ Res (1985) 0.82
A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin Endocrinol (Oxf) (1996) 0.82
Protective effects of a novel perfluorochemical emulsion in photodynamic therapy. Biomater Artif Cells Immobilization Biotechnol (1992) 0.82
A new high-glucuronidase mouse tumor curable by aniline mustard therapy. Cancer Treat Rep (1977) 0.82
The effect of cysteine on the immunosuppressive activity of busulphan, cyclophosphamide and nitrogen mustard. Br J Cancer (1971) 0.82
Time-dependence and selectivity of immunosuppressive agents. Immunology (1979) 0.82
Enzyme activated anti-tumour agents--III. Hydrolysis of conjugates of p-hydroxyaniline mustard in aqueous solution. Biochem Pharmacol (1976) 0.82
Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. Clin Cancer Res (1999) 0.81
Effect of cyclophosphamide on the homograft response in the guinea pig. Transplantation (1965) 0.81
Transplantation and immunosuppression. Mod Trends Immunol (1967) 0.81
Effect of some metabolic inhibitors on plaque formation in Jerne plates. Nature (1967) 0.81
Flavone acetic acid: is vascular shutdown the crucial mechanism of action. Int J Radiat Biol (1991) 0.81